29 Participants Needed

Cellularized Integra® for Burns

(Integra®-SC Trial)

Recruiting at 1 trial location
MG
Overseen ByMarc G Jeschke, MD PhD
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: Hamilton Health Sciences Corporation
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the treatment Integra®-SC for burns?

Integra, an artificial skin, has been shown to decrease the length of hospital stay for severely injured burn patients, especially those with multiple risk factors. It also provides protection against fluid loss and bacterial invasion, leading to functionally and aesthetically acceptable scar formation.12345

Is Cellularized Integra® safe for use in humans?

Integra, an artificial skin substitute, has been used in treating burns and has shown to be generally safe, though infections are a common complication. In a study, 42% of patients experienced infections, often involving bacteria like Pseudomonas aeruginosa and Staphylococcus aureus, suggesting that careful application and monitoring are important to reduce infection risks.24567

How does the treatment Integra®-SC differ from other treatments for burns?

Integra®-SC is unique because it is an artificial skin substitute that provides immediate full-thickness reconstruction for burns, using a collagen/glycosaminoglycane matrix and a silicon layer to protect tissue and promote the formation of a new dermis. This approach is particularly beneficial for massive burns where donor skin is limited, offering superior functional and cosmetic outcomes compared to traditional methods.23458

What is the purpose of this trial?

Burn injuries are one of the most severe skin injuries and lead to a complex wound healing response. When the skin is wounded, stem cells in the skin must respond fast to help repair the injured tissue. The damaged skin of burn patients contains cells that are still alive and have typical stem cell characteristics. Because stem cells are so important for wound healing, the investigators have combined them with an existing skin substitute, Integra®, to examine the potential wound healing benefits of these stem cells. This is an investigational treatment and a first in-human trial. The purpose of this study is to test the safety of using a patient's own stem cells combined with Integra®, which the investigators call Integra®-Stem Cells (Integra®-SC). The investigators hypothesize that Integra®-SC will result in improved wound healing, better scar quality, and decreased scar formation at one-year post-injury.

Research Team

MG

Marc G Jeschke, MD PhD

Principal Investigator

Hamilton Health Sciences Corporation

Eligibility Criteria

Adults with burns covering at least 5% of their body, needing surgery, and admitted within 120 hours after the burn can join. The trial is not for those with active cancer treatments, severe health conditions, certain infections (HIV, Hepatitis B/C, HTLV, Syphilis or West Nile Virus), burns only on face/hands or if pregnant.

Inclusion Criteria

Injury location includes a contralateral area
At least 5% of my body is affected.
I have a severe burn that needs surgery.
See 1 more

Exclusion Criteria

Pregnancy
Patients who are moribund
I do not have infections like HIV, Hepatitis B/C, HTLV, Syphilis, or West Nile Virus.
See 2 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive Integra® or Integra®-SC applied to the wound surface after removal of temporary wound coverage

1-4 months
Multiple visits during acute hospitalization

Follow-up

Participants are monitored for safety and effectiveness after treatment, including scar formation and wound healing

1 year post-discharge
Follow-ups at approximately 30, 60, 90, 180, and 365 days post-discharge

Treatment Details

Interventions

  • Integra®-SC
Trial Overview This study tests a new treatment combining a patient's own stem cells with Integra®, a skin substitute. Named Integra®-SC, it aims to improve wound healing and reduce scarring in burn patients. It's the first time this method is being tried on humans.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Integra®-SCExperimental Treatment1 Intervention
After removal of the temporary wound coverage (allograft), Integra®-SC is applied to the contralateral area of the site where Integra® is applied.
Group II: ControlActive Control1 Intervention
After removal of the temporary wound coverage (allograft), Integra® is applied directly onto the wound surface.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Hamilton Health Sciences Corporation

Lead Sponsor

Trials
380
Recruited
345,000+

Sunnybrook Health Sciences Centre

Lead Sponsor

Trials
693
Recruited
1,569,000+

Stem Cell Network

Collaborator

Trials
9
Recruited
600+

Ontario Institute for Regenerative Medicine

Collaborator

Trials
2
Recruited
60+

AFP Innovation Fund

Collaborator

Trials
9
Recruited
1,500+

Findings from Research

Integra, an artificial skin substitute, has been increasingly used in Germany for treating extensive full-thickness burns and posttraumatic reconstruction, highlighting its evolving role in burn therapy over the past 6 years.
The study emphasizes the importance of skilled surgical handling of Integra to ensure its effectiveness as a reconstructive dermal substitute for severely burned or posttraumatic patients, and aims to provide guidelines for its proper use.
Update on the use of collagen/glycosaminoglycate skin substitute-six years of experiences with artificial skin in 15 German burn centers.Heitland, A., Piatkowski, A., Noah, EM., et al.[2018]

References

Correlation of clinical outcome of integra application with microbiologic and pathological biopsies. [2018]
[Incidence and microbiology of infectious complications with the use of artificial skin Integra in burns]. [2022]
Use of Integra artificial skin is associated with decreased length of stay for severely injured adult burn survivors. [2022]
[Administration of Integra on primary burn wounds and unstable secondary scars]. [2019]
The use of a bilaminate artificial skin substitute (Integra) in acute resurfacing of burns: an early experience. [2005]
Longitudinal assessment of Integra in primary burn management: a randomized pediatric clinical trial. [2007]
Functional results of burned hands treated with Integra®. [2022]
Update on the use of collagen/glycosaminoglycate skin substitute-six years of experiences with artificial skin in 15 German burn centers. [2018]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security